BACKGROUND: Neuropsychological studies have extensively described the presence of cognitive dysfunction in MS patients. One possible pharmacological treatment of the impairment could be based on acetylcholinesterase inhibitors (AChEIs), which have shown efficacy in alleviating cognitive impairment in many other disorders. The findings on the efficacy of AChEI medication in MS associated cognitive symptoms are preliminary and no studies concerning cerebral acetylcholinesterase (AChE) activity in these patients have been published. OBJECTIVE: The objective of the study was to examine cerebral AChE activity in cognitively deteriorated MS patients. Cerebral AChE activity of 10 MS patients with secondary progressive disease and marked cognitive impairment, and 10 healthy controls, was studied with positron emission tomography using tracer (11)C-MP4A. METHODS: The cognitive profile of the patients was assessed with CERAD (Consortium to Establish a Registry for Alzheimer's Disease). RESULTS: No differences in cortical AChE activity between MS patients and controls were seen. CONCLUSIONS: In the patient group regional AChE activities had inverse correlations with Word learning and MMSE (Mini-Mental State Examination) scores. In the group of cognitively deteriorated MS patients no change in cerebral AChE activity, compared with controls, was observed, but within the patient group more pronounced cognitive symptoms were associated with higher cerebral AChE activity.
BACKGROUND: Neuropsychological studies have extensively described the presence of cognitive dysfunction in MSpatients. One possible pharmacological treatment of the impairment could be based on acetylcholinesterase inhibitors (AChEIs), which have shown efficacy in alleviating cognitive impairment in many other disorders. The findings on the efficacy of AChEI medication in MS associated cognitive symptoms are preliminary and no studies concerning cerebral acetylcholinesterase (AChE) activity in these patients have been published. OBJECTIVE: The objective of the study was to examine cerebral AChE activity in cognitively deteriorated MSpatients. Cerebral AChE activity of 10 MSpatients with secondary progressive disease and marked cognitive impairment, and 10 healthy controls, was studied with positron emission tomography using tracer (11)C-MP4A. METHODS: The cognitive profile of the patients was assessed with CERAD (Consortium to Establish a Registry for Alzheimer's Disease). RESULTS: No differences in cortical AChE activity between MSpatients and controls were seen. CONCLUSIONS: In the patient group regional AChE activities had inverse correlations with Word learning and MMSE (Mini-Mental State Examination) scores. In the group of cognitively deteriorated MSpatients no change in cerebral AChE activity, compared with controls, was observed, but within the patient group more pronounced cognitive symptoms were associated with higher cerebral AChE activity.
Authors: Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries Journal: J Neuroimmune Pharmacol Date: 2014-05-09 Impact factor: 4.147
Authors: T Antonelli; M C Tomasini; M Castellazzi; P Sola; C Tamborino; D Ferraro; L Ferraro; E Granieri Journal: Neurol Sci Date: 2012-12-18 Impact factor: 3.307
Authors: Evert-Jan Kooi; Marloes Prins; Natasha Bajic; Jeroen A M Beliën; Wouter H Gerritsen; Jack van Horssen; Eleonora Aronica; Anne-Marie van Dam; Jeroen J M Hoozemans; Paul T Francis; Paul van der Valk; Jeroen J G Geurts Journal: Acta Neuropathol Date: 2011-06-21 Impact factor: 17.088